← Figs overview

Figs vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Figs Inc (FIGS)

Q3 2026
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

August 2026
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

Latest
▲3

FIGS raises 2026 outlook on strong Q2 and international surge

  • FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.

    This is the core new event that directly drives the stock higher.

  • International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.

    Shows a key new growth driver that justifies the raised outlook.

  • Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.

    New analyst actions and cash flow metrics that influence investor perception.

  • Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.

    A new regulatory risk that could hurt supply, but with limited impact.

Neogen Corporation (NEOG)

Q3 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.